Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

7.850 -0.150 (-1.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,283,010
Open 8.000
Bid (Size) 7.800 (1)
Ask (Size) 8.050 (2)
Prev. Close 8.000
Today's Range 7.740 - 8.115
52wk Range 6.330 - 14.23
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Gene Editing Stock to Buy Now, and 1 to Sell
Target markets matter. So does having the cash to get to them. 
Via The Motley Fool
Editas Medicine Announces Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire

Performance

YTD
-6.99%
-6.99%
1 Month
-10.90%
-10.90%
3 Month
-1.88%
-1.88%
6 Month
+5.37%
+5.37%
1 Year
-38.29%
-38.29%

More News

Read More
Analyst Expectations for Editas Medicine's Future
Via Benzinga
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
Via The Motley Fool
Expert Ratings for Editas Medicine
Via Benzinga
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Is Editas Medicine Stock a Buy Now?
Via The Motley Fool
What 6 Analyst Ratings Have To Say About Editas Medicine
Via Benzinga
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
From Editas Medicine, Inc.
Via GlobeNewswire
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
Via Talk Markets
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
Via The Motley Fool
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
2 Short-Squeeze Candidates That Could Go Parabolic
Via The Motley Fool
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Editas Medicine Announces Pricing of Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
Via Benzinga
5 Stocks to Buy With Explosive 500% Potential
Via InvestorPlace
Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
Via Benzinga
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
From Editas Medicine, Inc.
Via GlobeNewswire
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Via InvestorPlace
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
From Editas Medicine, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.